April 25th – 27th 2019

Workshop & Symposium

„Tumor Immunology meets Oncology XV“

Institute of Medical Immunology
Prof. Dr. Barbara Seliger
Dear colleagues and friends,

welcome in Halle for our meeting „Tumor immunology meets oncology (TIMO XV)“, which started 15 years ago. Every year the meeting gained recognition and became greater due to the high level scientific contributions and the invaluable enthusiasm of all participants. This conference provides a platform for preclinical and translational researchers as well as for clinicians involved in tumor immunology and immunotherapy by addressing emerging topics like advances in molecular immunology, news in immunotherapy, combination therapies, tumor microenvironment, immune resistance mechanisms and biomarkers.

We are happy and privileged to attract again an extraordinary group of national and international scientists and clinicians as speakers for this years TIMO meeting. Furthermore, this meeting also represents the main activity of the working group „Tumor immunology“ of the German Society of Immunology, which aims at building up a network in order to improve the knowledge of anti-tumor immune response, to provide rationales for implementing immunotherapeutic approaches, but also to promote young scientists/clinicians to present their own work and to discuss novel methods and tools for tumor immunologic research.

We would like to welcome you to Halle and wish you all an exciting workshop and symposium. In addition, we hope that you will have a pleasant stay and leave with impressions of the beauty and hospitality of the city, with a lot of new ideas and novel insights for your own basic and/or translational research and with new friends/collaborators.

We express our gratitude to all who were involved in the organization of this event and gratefully acknowledge our sponsors for supporting this meeting as well as the participants for joining us.

Prof. Dr. Barbara Seliger & Maria Heise
**Workshop program „Tumor immunology”**

**Date:** 25th of April 2019  
**Venue:** University Hospital Halle, Building 6, Lecture Hall, Ernst-Grube-Straße 40, 06120 Halle

**12.00 – 12.15 p.m.**  
**Introduction**  
Barbara Seliger (Halle, GER)

**Chair:** Dagmar Riemann (Halle)  
Marc Schmitz (Dresden)

**12.15 – 12.30 p.m.**  
Immune sculpting of the breast cancer genome  
Thomas Karn (Frankfurt, GER)

**12.30 – 12.45 p.m.**  
Breast cancer and immunomonitoring  
Chiara Massa (Halle, GER)

**12.45 – 01.00 p.m.**  
Killing melanoma cells with ROS provides immunoprotection against tumor growth in vivo  
Sander Bekeschus (Greifswald, GER)

**01.00 – 01.15 p.m.**  
Diet-induced vitamin D insufficiency alters immune cell composition of Balb/c mice  
Carina Matos (Regensburg, GER)

**01.15 – 01.30 p.m.**  
LDHB overexpression alters mitochondrial metabolism in human CD4⁺ T cells  
Sonja Decking (Regensburg, GER)

**01.30 – 01.45 p.m.**  
IFN-γ-dependent bystander killing of melanoma cells by CD8⁺ T cells and mechanisms of resistance  
Beatrice Thier (Essen, GER)

**01.45 – 02.00 p.m.**  
Regulatory T cells in an endogenous lymphoma mouse model evolve an increasingly suppressive phenotype and are targeted by immune checkpoint inhibitors  
Vera Bauer (München, GER)

**02.00 – 02.30 p.m. Coffee break**

**Chair:** Dieter Kabelitz (Kiel)  
Gottfried Baier (Innsbruck)

**02.30 – 02.45 p.m.**  
Inflammation related microRNAs and bone marrow micro-environment, as indicators of disease progression in patients with myelodysplastic syndromes  
Christoforos Vaxevanis (Halle, GER)

**02.45 – 03.00 p.m.**  
The inflammasome of tumor cells in colorectal cancer: a potential target to strengthen the Th1/Tc1 response of tumor infiltrating T lymphocytes (TILs)  
Linda Bilonda Mutala (Nantes, FR)

**03.00 – 03.15 p.m.**  
CIK cells retargeting with monoclonal antibodies against hematological malignancies  
Pierangela Palmerini (Padova, ITA)

**03.15 – 03.30 p.m.**  
Engaging UniCAR T cells via short-lived and longer lasting target modules  
Claudia Arndt (Dresden, GER)

**03.30 – 03.45 p.m.**  
Antigen specific adoptive CD4⁺ T cell transfer immunotherapy against melanoma causes reactive neutrophil response  
Bastian Kruse (Magdeburg, GER)

**03.45 – 04.00 p.m.**  
HopQ mediated binding of Helicobacter pylori to CEACAM1 or CEACAM5 as novel factor that modulates the risk of H. pylori caused gastric cancer  
Bernhard B. Singer (Essen, GER)
04.00 – 04.30 p.m. Coffee break

Chair:  Stina Wickström (Stockholm)
       Michael Bachmann (Dresden)

04.30 – 04.45 p.m.
Clinical impact of infiltrating plasmacytoid dendritic cells in colon cancer
Maximilian Kiessler (Dresden, GER)

04.45 – 05.00 p.m.
Integrative -omics analysis to identify drug targets for ccRCC immunotherapy
Anna Reustle (Stuttgart, GER)

05.00 – 05.15 p.m.
Advanced NGS application in medical research
Yuanyuan Chen (Beijing, CHN)

05.15 – 05.30 p.m.
Epigenetic immune cell quantification - a novel approach for minimally invasive immune cell profiling
Christoph Sachsenmaier (Berlin, GER)

05.30 – 05.45 p.m.
Integrative cancer immunology: clinical translation of IO biomarkers and the immunoscore
Helen Angell (Cambridge, UK)

05.45 – 06.00 p.m.
Immune phenotyping from measurements of the circulating proteome
Heinrich Röder (Boulder, USA)
Poster session „Tumor immunology”

**Date:** 25th of April 2019, 06.00 – 07.30 p.m.

**Venue:** University Hospital Halle, Building 6, Lobby, Ernst-Grube-Straße 40, 06120 Halle

**Chair:** Joe Poh Sheng Yeong (Singapore, SGP)  
Mathieu Bléry (Marseille, FRA)

1. Transcriptional and post-transcriptional regulation of MHC class I expression in breast cancer and melanoma  
Karthikeyan Subbarayan, Maria-Filothei Lazaridou (Halle, GER)

2. Targeting the coding sequence: microRNAs regulate classical and non-classical HLA molecules  
Michael Friedrich (Halle, GER)

3. Physical plasma-treated saline promotes an immunogenic phenotype in CT26 colon cancer cells in vitro and in vivo  
Eric Freund (Greifswald, GER)

4. The immunogenicity of oxidized ovalbumin  
Ramona Clemen (Greifswald, GER)

5. Influences of metabolism on the functional properties of vaccine DC  
Chiara Massa (Halle, GER)

6. Establishment of a NGS gene panel for determination of tumor mutational burden in lung adenocarcinoma  
Anne Vogel (Mainz, GER)

7. Differential effects of tyrosine kinase inhibitors on T cell based immunotherapy of acute myeloid leukemia  
Frederick Fasslirinner (Dresden, GER)

8. Multispectral imaging (MSI) of the immune cell infiltrate of bone marrow biopsies in MDS and sAML  
Marcus Bauer (Halle, GER)

9. Improvement of UniCAR T cell effectiveness against EGFR⁺-tumor cells by using different αEGFR targeting module formats  
Justyna Jureczek (Dresden, GER)

10. Engineering human T cells with a novel switchable CAR technology for tumor immunotherapy  
Anja Hoffmann (Dresden, GER)

11. NF-κB activation triggers NK-cell stimulation by monocyte-derived dendritic cells  
Naomi Bosch (Erlangen, GER)

12. In vitro analysis of a novel therapeutic biomarker for antibody-based therapy of triple negative breast cancer  
Claudia Müller (Leipzig, GER)

13. Characterizing known CD44 regulatory microRNAs as putative therapeutic agents in human melanoma  
Simon Jasinski-Bergner (Halle, GER)

14. Cancer vaccines: designing artificial synthetic long peptides to improve presentation of class I and class I I T cell epitopes by DC  
Catherine Rabu (Nantes, FR)

15. Novel target modules for retargeting of UniCAR T cells to sialyl-Tn expressing tumor cells  
Liliana Loureiro (Dresden, GER)
Symposium program „Tumor immunology”

Date: 26th of April 2019
Venue: University Hospital Halle, Building 6, Lecture Hall, Ernst-Grube-Straße 40, 06120 Halle

08.15 a.m.
Welcome and introduction
Dean of the Faculty: Michael Gekle
Organizer: Barbara Seliger

Session: Novel insights into biomarkers immune modulation

Chair: Shuji Ogino/ Pamela Ohashi

08.30 – 09.00 a.m.
Role of pathology in the prediction of response to immuno-oncological therapies
Arndt Hartmann (Erlangen, GER)

09.00 – 09.30 a.m.
Revisiting an old story in the context of immunotherapies: HLA class I abnormalities in tumors
Barbara Seliger (Halle, GER)

09.30 – 10.00 a.m.
Regulation of radiation-induced tumor immunogenicity by TREX1
Sandra Demaria (New York, USA)

11.00 – 11.30 a.m.
In vivo veritas - visualizing and targeting immune cell cancer interactions
Andreas Beilhack (Würzburg, GER)

11.30 – 12.00 a.m.
Inhibitory mechanisms in the tumor microenvironment
Pamela Ohashi (Toronto, CAN)
SITC-Sponsored Speaker

12.00 – 01.00 p.m.
LUNCH BREAK AND POSTER VIEWING

Key note lecture
Chair / Introduction: Barbara Seliger

01.00 – 01.45 p.m.
Integrative analyses of environment, microbiome, genomics, and immunity for precision medicine: new opportunities
Shuji Ogino (Boston, USA)

Session: Host tumor interaction, NK cells and therapy

Chair: Cornelis Melief/ Sandra Demaria

01.45 – 02.15 p.m.
Recognition of fungi by NK cells
Ofer Mandelboim (Jerusalem, ISR)

02.15 – 02.45 p.m.
Next generation immunotherapies: targeting innate lymphocytes and tumor microenvironment
Mathieu Bléry (Marseille, FRA)

02.45 – 03.15 p.m.
Perspectives of γδT cells in cancer immunotherapies
Dieter Kabelitz (Kiel, GER)

03.15 – 03.45 p.m. Coffee break
Session: Novel targets of immunotherapy, biomarkers and resistances

Chair: Christopher A. Klebanoff/ Sibylle Loibl

03.45 – 04.15 p.m.
Effects of changes in the life style on the immunity of cancer patients
Licia Rivoltini (Milano, ITA)

04.15 – 04.45 p.m.
Orphan nuclear receptor NR2F6 as alternative immune checkpoint in the T cell compartment
Gottfried Baier (Innsbruck, AUT)

04.45 – 05.15 p.m.
T cell repertoire analyses in immunotherapy-treated melanoma patients
Nathalie Labarrière (Nantes, FRA)

05.15 – 05.45 p.m.
Biomarkers to predict responsiveness in Asian cancers treated with immune checkpoint blockade
Joe Poh Sheng Yeong (Singapore, SGP)
Workshop program „Tumor immunology”

**Date:** 27th of April 2019  
**Venue:** University Hospital Halle, Building 6, Lecture Hall, Ernst-Grube-Straße 40, 06120 Halle

**Session: Immunotherapeutic approaches**

**Chair:** Joost Kreijtz / Bernard A. Fox

08.15 – 08.45 a.m.  
Reversing immunotherapy resistance, understanding mechanisms and designing strategies  
Samir Khleif (Washington, USA)

08.45 – 9.15 a.m.  
Therapeutic HPV16 vaccination is effective as mono-therapy in pre-malignant disease, but requires combination treatment in HPV16-induced cancers  
Cornelis Melief (Leiden, NLD)

09.15 – 09.45 a.m.  
When checkpoint inhibitors fail; could ACT be an option?  
Stina Wickström (Stockholm, SWE)

09.45 – 10.15 a.m.  
T cell therapy 2.0: building the next generation of adoptive cancer immunotherapies  
Christopher A. Klebanoff (New York, USA)

10.15 – 10.45 a.m. **Coffee break**

**Session: Novel strategies and therapy combinations**

**Chair:** Licia Rivoltini/ Ofer Mandelboim

11.15 – 11.45 a.m.  
Checkpoint inhibitors in breast cancer therapy – update of recent results and running trials  
Sibylle Loibl (Neu-Isenburg, GER)

11.45 – 12.15 p.m.  
Targeting innate immunity to enhance cancer immunotherapy  
Joost Kreijtz (Oss, NLD)

12.15 – 12.45 p.m.  
Strategies to monitor and optimize costimulatory effects of T cell agonists and rescue them from the dustbin of failed single agents  
Bernard A. Fox (Portland, USA)

12.45 – 13.00 p.m. **Wrap up and closing remarks**  
Jörg Wischhusen (Würzburg, GER)
REGISTRATION FEE:

200€ - payable until 2019, 20th of April or cash at the registration desk.

MLU members will be charged for 75€, Bachelor/ Master students for free

Registration could be waived in special cases (Please bring in your MLU/UKH ID card)

Bank name:
Deutsche Apotheker- und Aerztebank
IBAN: DE46300606011008814171
SWIFT code: DAAEDEDD
reason for payment: name, reg. fee TIMO XV

SYMPHOSIUM SECRETARY:

Maria Heise
Institute of Medical Immunology
Martin Luther University Halle-Wittenberg
Magdeburger Straße 2, 06097 Halle (Saale)

Tel. +49 (0) 345 557 5041 / or -1357
Fax +49 (0) 345 557 4055

e-mail: immunologie@uk-halle.de

The Medical Association of Saxony-Anhalt credits this educational activity with 8 points (workshop) and 12 points (symposium). You will receive a certificate of attendance on site at the registration desk.

WE THANK OUR SPONSORS:

AstraZeneca GmbH, Becton Dickinson GmbH, Biodexis, Bristol-Meyers Squibb (3.000€), Celgene GmbH (2.000€), Cellex PT, City of Halle, cureVac AG, Deutsche Forschungsgesellschaft (DFG), Epimune GmbH, Fluidigm, GEMoAB GmbH, Immudex USA, INTAVIS, Lipocalyx GmbH, Merck Serono GmbH (1.300€), Miltenyi Biotec GmbH, MSD GmbH (1.500€), Novogene (1.300€), Roche Pharma AG (2.000€), Sarstedt, Steintor-Varieté, SERVA GmbH, Thermo Fisher Scientific, QIAGEN GmbH
CONFERENCE VENUE:

University Hospital Halle
Ernst-Grube-Strasse 40; 06120 Halle
Building 6, Lecture Hall

Airport or main train station transportation:
Various taxi companies service the airport Leipzig or the main train station Halle. A cab ride costs approx. 50 € from the airport to the clinic and from the train station to the Conference venue approx. 12 €. In addition, public train service is available from the airport to Halle (every 30 min.).

From the main train station in Halle you can take the tram no. 4 or 5, direction Heide or Kroellwitz.

PARKING INFORMATION:
Several parking facilities are located next to the Ernst-Grube-Street. Please follow the sign „Parkplatz Universitätsklinik“.

PHOTOS:
Photos by © Michael Hoetzel, DGPh
In Institute of Medical Immunology

Prof. Dr. Barbara Seliger
Director of FOCIS Center of Excellence

Martin-Luther-University Halle-Wittenberg
Medical Faculty
Magdeburger Straße 2
06112 Halle (Saale)
Tel. +49 (0) 345 557 5041 / or -1357
Fax +49 (0) 345 557 4055
e-mail: immunologie@uk-halle.de

in cooperation with the

and

Society for Immunotherapy of Cancer